XML 139 R103.htm IDEA: XBRL DOCUMENT v3.22.4
Share capital and Contributed Surplus - (B) Warrants (C) Contributed Surplus (Narrative) (Details)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Apr. 30, 2021
CAD ($)
$ / shares
May 31, 2020
CAD ($)
Mar. 31, 2020
CAD ($)
Sep. 30, 2020
CAD ($)
share
$ / shares
shares
Sep. 30, 2022
CAD ($)
share
$ / shares
shares
Sep. 30, 2021
CAD ($)
share
$ / shares
shares
Sep. 30, 2020
shares
Dec. 31, 2019
CAD ($)
share
Mar. 31, 2022
shares
Disclosure of classes of share capital [line items]                  
Description of warrants exercise         the warrant holder must exercise 70 warrants to receive one common share.        
Cash commission       $ 164,716 $ 33,880 $ 606,622   $ 0  
Number of share options granted | share       29,357 9,500 52,988   0  
Estimated life       4 years 1 month 24 days 3 years 5 months 23 days        
Expected volatility       67.71% 90.48% 76.46% 67.71%    
Risk-free interest rate       0.65% 2.04% 0.35% 65.00%    
Share issue related cost   $ 58,065 $ 45,283 $ 699,886 $ 33,880 $ 606,622      
Number of compensation options exercised | shares           2,459      
Gross proceeds from option exercises           $ 215,148      
Number of options outstanding | shares           837      
Description of maximum term of options granted       five years          
Stock options available for grant under the plan | shares       30,113     30,113    
Weighted average exercise price of share options granted | $ / shares       $ 45.5 $ 69.59 $ 104.3      
Weighted average vesting period of options       10 months 13 days 10 months 17 days 1 year 9 months 25 days      
Weighted-average fair value of stock options | $ / shares       $ 16.1 $ 38.21 $ 50.4      
Number of options with accelerated vesting | shares           5,507      
Number of options with accelerated cancellation | shares           3,571      
Additional stock based compensation charges           $ 65,813      
Number of other equity instruments granted | share         28,668 21,412      
Shared-based compensation expense       $ 283,084 $ 1,960,072 $ 2,462,207   $ 0  
April 2021 Offering [Member]                  
Disclosure of classes of share capital [line items]                  
Cash commission $ 288,405                
Number of share options granted 3,296                
Exercise price, share options granted | $ / shares $ 87.5                
Option exercisable term two years                
Description of stock option warrants exercise Each Compensation Option Warrant is exercisable to acquire 1/70 of a Common Share (a "Compensation Option Warrant Share") at a price of $1.75 per Compensation Option Warrant Share (70 Compensation Option Warrant for one Compensation Option Warrant Share) for a period of 24 months from the closing of the Offering.                
Fair value per compensation option | $ / shares $ 77                
Estimated life 2 years                
Underlying stock price | $ / shares $ 90.3                
Exercise price of outstanding share options | $ / shares $ 87.5                
Expected volatility 80.00%                
Risk-free interest rate 0.31%                
Expected discount rate 0.00%                
Share issue related cost $ 233,057                
Long-Term Incentive Plan [Member]                  
Disclosure of classes of share capital [line items]                  
Maximum number of common shares issuable under plan | shares                 60,382
Stock options available for grant under the plan | shares         19,833        
Number of share units available for grant under plan | shares         27,503        
Restricted share units [Member]                  
Disclosure of classes of share capital [line items]                  
Number of other equity instruments granted | share         10,726 16,412      
Weighted-average grant date fair value         $ 43.5 $ 105.7      
Weighted average vesting period of other equity instruments         2 months 4 days 8 months 8 days      
Performance stock units [Member]                  
Disclosure of classes of share capital [line items]                  
Number of other equity instruments granted | share         17,942 2,857      
Weighted-average grant date fair value         $ 126.7 $ 105      
Weighted average vesting period of other equity instruments           4 months 24 days      
Share appreciation rights [Member]                  
Disclosure of classes of share capital [line items]                  
Number of other equity instruments granted | share         514 2,143      
Weighted average exercise price of other equity instruments granted | $ / shares         $ 126.7 $ 115.5